The global cough assist devices market was valued at USD 262.2 million in 2025 and is projected to reach USD 412.8 million by 2032, registering a CAGR of 6.7% during the forecast period. Cough assist devices, also known as mechanical insufflation-exsufflation (MI-E) devices, are non-invasive respiratory support systems designed to help patients with impaired cough function effectively clear airway secretions. These devices are widely used in the management of neuromuscular disorders, spinal cord injuries, chronic respiratory diseases, and other conditions associated with weakened respiratory muscles. Rising prevalence of chronic respiratory diseases, increasing incidence of neuromuscular disorders, and the growing geriatric population are among the key factors driving market growth.

Market expansion is further supported by the growing shift toward home healthcare, increasing awareness regarding non-invasive airway clearance therapies, and continuous advancements in portable respiratory care technologies. Manufacturers are focusing on developing compact, battery-powered devices integrated with digital monitoring capabilities to improve patient compliance and enable remote disease management. Favorable reimbursement in developed markets, increasing healthcare expenditure, and expanding respiratory care infrastructure are also contributing to market growth. North America currently dominates the global market owing to its advanced healthcare infrastructure and high adoption of respiratory care technologies, while Asia Pacific is expected to witness the fastest growth due to improving healthcare access and increasing diagnosis of respiratory disorders.

Key Highlights of the Report

• By product, automatic cough assist devices dominate the global cough assist devices market, owing to their ease of operation, programmable treatment settings, and increasing adoption in hospitals and home healthcare environments.

• Manual cough assist devices are expected to witness steady growth, supported by their affordability and increasing utilization in resource-limited healthcare settings.

• By indication, neuromuscular disorders account for the largest market share, driven by the high prevalence of conditions such as amyotrophic lateral sclerosis (ALS), muscular dystrophy, and spinal muscular atrophy that impair natural cough function.

• Chronic respiratory diseases are projected to witness significant growth, fueled by the increasing burden of chronic obstructive pulmonary disease (COPD), bronchiectasis, and other pulmonary disorders requiring airway clearance support.

• Spinal cord injury applications continue to represent an important market segment, owing to compromised respiratory muscle function and long-term respiratory care requirements.

• By end use, hospitals dominate the market, supported by high patient volumes, availability of specialized respiratory care professionals, and widespread use of advanced airway clearance technologies.

• Home care settings are expected to register the fastest growth, driven by increasing preference for home-based respiratory management, reduced hospital stays, and growing adoption of portable respiratory devices.

• Long-term care facilities continue to expand their adoption of cough assist devices, owing to the growing elderly population and increasing prevalence of chronic respiratory conditions.

• The rising prevalence of chronic respiratory diseases and neuromuscular disorders remains one of the primary market drivers, increasing demand for effective non-invasive airway clearance therapies.

• The growing global geriatric population is accelerating market growth, as age-related decline in respiratory muscle strength increases the need for assisted cough therapies.

• Technological advancements in portable, battery-powered, and digitally connected cough assist devices are improving treatment accessibility, supporting greater adoption in home healthcare settings.

• The integration of telehealth and remote patient monitoring capabilities is creating new growth opportunities, enabling clinicians to monitor treatment adherence and optimize respiratory care remotely.

• North America dominates the global cough assist devices market, supported by advanced healthcare infrastructure, favorable reimbursement policies, high diagnosis rates, and strong adoption of respiratory care technologies.

• Asia Pacific is anticipated to witness the fastest growth, driven by improving healthcare infrastructure, increasing awareness of respiratory disorders, expanding home healthcare services, and rising healthcare investments.

• The competitive landscape is moderately consolidated, with leading companies focusing on portable device development, digital connectivity, strategic collaborations, and expansion of respiratory care product portfolios to strengthen their market position.

Key Company Profiles

• ABM Respiratory Care
• Air Liquide Healthcare
• Baxter
• Dima Italia
• Philips
• Seoil Pacific
• ICU Medical
• Ventec Life Systems
• West Care Medical
• Vitalograph

For more details, please visit: https://apeloconsulting.com/product/global-cough-assist-devices-market-and-forecast-to-2032/

Data Source

Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.